By: IPP Bureau
Last updated : December 22, 2025 7:18 pm
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Samsung Biologics has reached a definitive agreement to acquire Human Genome Sciences from GSK for $280 million. The deal, executed through its U.S. subsidiary, marks the company’s first manufacturing foothold in the United States.
The facility features two cGMP plants with a combined 60,000 liters of drug substance capacity, capable of handling both clinical and commercial-scale production.
Samsung Biologics will retain over 500 existing employees to ensure stability. The company also plans further investments to upgrade technology and expand capacity.
Located in the Rockville, Maryland bio-cluster, the site secures Samsung Biologics’ long-term commitment to the U.S. market and enhances its global CDMO network.
The transaction is expected to close by the end of Q1 2026.
By integrating this U.S. site with its existing Korean hubs, Samsung Biologics aims to offer clients flexible, multi-site production options to strengthen the supply chain for critical biologic medicines.
Samsung Biologics has established a proven track record of operational and construction excellence through on-time completion of its Bio Campus I and II, and also recently secured land for Bio Campus III, which will house distinct R&D and manufacturing programs for new modalities. With 785,000 liters of capacity across five plants, the industry’s leading capacity, Samsung Biologics continues to advance its diversified portfolio spanning monoclonal antibodies, antibody-drug conjugates (ADCs), mRNA, organoid-based services, and next-generation therapies.
“This landmark acquisition is a testament to our unwavering commitment to advancing global healthcare and bolstering our manufacturing capabilities in the U.S. The investment will enable us to deepen our collaboration with federal, state, and local stakeholders to best serve our customers and partners while ensuring a reliable and stable supply of life-saving therapeutics,” said John Rim, CEO and President of Samsung Biologics. “This marks an important step forward in our mission to achieve a better life through biomedicines, and we look forward to building on the legacy of this facility as we welcome experienced colleagues to the Samsung Biologics family and continue delivering innovative solutions that make a meaningful impact.”
Regis Simard, President, Global Supply Chain, GSK, said: "Today’s agreement to divest the Rockville manufacturing site to our valued long-term partner, Samsung Biologics, will secure the manufacture of two important medicines on US soil for US patients and further build GSK’s supply chain resilience. Along with GSK’s recent commitment to invest $30bn in R&D and manufacturing in the US over the next 5 years, this deal enables us to further focus on building the agility, capacity and capability needed in our manufacturing network to deliver the next generation of specialty medicines and vaccines. I am confident in a positive partnership and future for the Rockville site.”